LLY · News · 20260930N

Regulatory Approval - Ebglyss extended dosing

ELI LILLY & Co · 2026-09-30 · Importance 34 · Surprise 42

Lilly reported positive Phase 3b ADtouch data for Ebglyss monotherapy in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis. More than half of patients achieved clear or almost clear hand and foot skin by Week 16, with significant clearance reported as early as one month. Significant itch relief began as early as two weeks, and nearly 80% of patients reported satisfaction or high satisfaction with hand clearance at Week 16. The results support further commercial and potentially regulatory positioning of Ebglyss for difficult-to-treat hand and foot disease.